Immunologist Thomas Hodge Dies of COVID-19 at 69

A former academic and consultant, Hodge cofounded the CrisiScience Collective to help combat the pandemic.

Written byLisa Winter
| 2 min read
Middle aged man with glasses wearing a blue shirt and tan blazer with a red paisley tie looking into the camera

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

ABOVE: © CHARLES WARDEN, ETSU

Immunologist and virologist Thomas Hodge III died on July 31 due to complications of COVID-19. He was 69. According to The Washington Post, Hodge was medically ineligible to be vaccinated against the disease.

Born and raised in Gainesville, Georgia, Hodge graduated from Emory University in nearby Atlanta in 1974, where he double-majored in biology and chemistry, according to his CV. He received his PhD in immunology from East Tennessee State University College of Medicine in 1982.

After graduation, he worked as an assistant professor of microbiology at the University of Alabama, Birmingham School of Medicine for four years, before leaving to join the US Centers for Disease Control and Prevention (CDC). Hodge was the section chief of molecular immunology in the division of HIV/AIDS pathogenesis at the CDC until 1993 when he took over as the division’s director of the immunogenetics laboratory, where he stayed ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

  • Lisa joined The Scientist in 2017. As social media editor, some of her duties include creating content, managing interactions, and developing strategies for the brand’s social media presence. She also contributes to the News & Opinion section of the website. Lisa holds a degree in Biological Sciences with a concentration in genetics, cell, and developmental biology from Arizona State University and has worked in science communication since 2012.

    View Full Profile
Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies